



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

July 23, 2007

Docket No. 03030292
Control No. 140429

License No. 06-13053-04

Joseph Catino, Ph.D.
Executive Vice President-Research
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175

SUBJECT: BAYER PHARMACEUTICALS CORPORATION, REQUEST FOR ADDITIONAL
INFORMATION CONCERNING APPLICATION FOR AMENDMENT TO
LICENSE, CONTROL NO. 140429

Dear Dr. Catino:

This is in reference to your letter dated April 17, 2007 requesting to amend Nuclear Regulatory Commission License No. 06-13053-04. We have received your letter dated July 9, 2007 with additional information. In order to continue our review, we need the following additional information:

1. In your letter dated July 9, 2007, you submitted the records associated with the disposals to the sanitary sewerage system for the year 2006. **All** records of release by disposal into sewer that exist for your license and previous licenses that were superseded by this current license must be submitted for radionuclides with a greater than a 120 day half life before termination.
2. Please state the units for the numbers displayed on your sewer disposal log.
3. The request for termination of the license doesn't appear to be signed by a senior executive management. Please submit a letter signed by senior management stating that they concur with the request for license termination.
4. Please confirm that you had no leaking sealed sources.
5. In your letter dated July 9, 2007, it is stated that room RB-007C must be a typographical error for RB-107C or RB-207C. Please submit surveys for room RB-107C or state why they are not needed.
6. In your letter dated July 9, 2007, it is stated that room RB-233 must be a typographical error for RB-231 or RB-232. Please submit surveys for room RB-231 or state why they are not needed.
7. Please confirm that you will follow 10 CFR 31.5 requirements for the transfer of the generally licensed items.

J. Catino
Bayer Pharmaceuticals Corporation

2

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Regulations, Guidance, and Communications**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 140429. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5366.

If we do not receive a reply from you within 30 calendar days from the date of this letter, we will assume that you do not wish to pursue your application.

Sincerely,

Original signed by Dennis R. Lawyer

Dennis R. Lawyer
Health Physicist
Commercial and R&D Branch
Division of Nuclear Materials Safety

cc:
Gary Toczylowski, Radiation Safety Officer

J. Catino
Bayer Pharmaceuticals Corporation

3

DOCUMENT NAME: C:\FileNet\ML072040465.wpd

SUNSI Review Complete: DLawyer

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	☒ N	DNMS/RI	☐	DNMS/RI	☐		☐
NAME	DLawyer/DRL							
DATE	7/23/2007							

OFFICIAL RECORD COPY